AstraZeneca (AZN) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: AstraZeneca is conducting a Phase 3b, multicenter, open-label, single-arm study titled ‘Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients.’ The study aims to evaluate the safety and efficacy of acalabrutinib, a drug intended for patients with chronic lymphocytic leukemia (CLL). This study is significant as it targets different patient cohorts, including treatment-naive, relapsed/refractory, and those with prior ibrutinib therapy, to assess the drug’s comprehensive impact.
Intervention/Treatment: The intervention being tested is acalabrutinib, an experimental drug administered as a 100 mg capsule taken orally twice daily. It is designed to treat patients with CLL by targeting specific pathways involved in the disease’s progression.
Study Design: This interventional study is non-randomized and follows a single-group assignment model. Participants are divided into three cohorts based on their treatment history. The primary purpose of the study is treatment, and there is no masking involved, meaning both researchers and participants know the treatment being administered.
Study Timeline: The study began on June 19, 2019, with an expected duration of approximately 72 months. The primary completion date is not specified, but the last update was submitted on November 28, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence clinical practices.
Market Implications: The update on this study could positively impact AstraZeneca’s stock performance by reinforcing investor confidence in the company’s oncology portfolio. As acalabrutinib addresses a significant medical need, successful outcomes may enhance AstraZeneca’s competitive position in the CLL treatment market, potentially affecting the dynamics within the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.
To learn more about AZN’s potential, visit the AstraZeneca drug pipeline page.